Page 28 - Portuguese Journal - SPORL - Vol 61. Nº2

inflammation. Front Cell Infect Microbiol. 2018 May management. J Allergy Clin Immunol. 2021 Jan;147(1):29-
23;8:168. doi: 10.3389/fcimb.2018.00168. 36. doi: 10.1016/j.jaci.2020.11.013
11.Cheng KJ, Wang SQ, Xu YY. Different roles of 23.Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N,
Staphylococcus aureus entero- toxin in different subtypes Bauters W. et al. Omalizumab is effective in allergic and
of nasal polyps. Exp Ther Med. 2017 Jan;13(1):321-326. doi: nonallergic patients with nasal polyps and asthma. J
10.3892/etm.2016.3951 Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.
12.Takeda K, Sakakibara S, Yamashita K, Motooka D, jaci.2012.07.047.
Nakamura S, El Hussien MA. et al. Allergic conversion of 24.Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N,
protective mucosal immunity against nasal bacteria in Lee SE. et al. Efficacy and safety of dupilumab in patients
patients with chronic rhinosinusitis with nasal polyposis. with severe chronic rhinosinusitis with nasal polyps
J Allergy Clin Immunol. 2019 Mar;143(3):1163-1175.e15. doi: (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results
10.1016/j.jaci.2018.07.006. from two multicentre, randomised, double-blind, placebo-
13.Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK. controlled, parallel-group phase 3 trials. Lancet. 2019 Nov
et al. Evidence for intranasal antinuclear autoantibodies 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1.
in patients with chronic rhinosinusitis with nasal polyps. 25.Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE.
J Allergy Clin Immunol. 2011 Dec;128(6):1198-1206.e1. doi: et al. Efficacy and safety of omalizumab in nasal polyposis:
10.1016/j.jaci.2011.08.037. 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020
14.Lan F, Zhang N, Holtappels G, De Ruyck N, Krysko Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032
O, Van Crombruggen K. et al. Staphylococcus aureus 26.Han JK, Bachert C, Fokkens W, Desrosiers M,
induces a mucosal type 2 immune response via epithelial Wagenmann M, Lee SE. et al. Mepolizumab for chronic
cell- derived cytokines. Am J Respir Crit Care Med. 2018 rhinosinusitis with nasal polyps (SYNAPSE): a randomised,
Aug 15;198(4):452-463. doi: 10.1164/rccm.201710-2112OC. double-blind, placebo-controlled, phase 3 trial. Lancet
15.Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-
A, White AA. et al. Defining appropriateness criteria 2600(21)00097-7.
for endoscopic sinus surgery during management of 27.Tversky J, Lane AP, Azar A. Benralizumab effect on
uncomplicated adult chronic rhinosinusitis: a RAND/UCLA severe chronic rhinosinusitis with nasal polyps (CRSwNP):
appropriateness study. Rhinology. 2016 Jun;54(2):117-28. a randomized double-blind placebo-controlled trial. Clin
doi: 10.4193/Rhino16.023. Exp Allergy. 2021 Jun;51(6):836-844. doi: 10.1111/cea.13852.
16.Reitsma S, Adriaensen GFJPM, Cornet ME, van Haastert 28.Doty RL, Kamath V. The influences of age on olfaction:
RM, Raftopulos MH, Fokkens WJ. The Amsterdam a review. Front Psychol. 2014 Feb 7;5:20. doi: 10.3389/
Classification of Completeness of Endoscopic Sinus fpsyg.2014.00020.
Surgery (ACCESS): a new CT-based scoring system grading 29.Fokkens W, Lund V, Mullol J. European position paper
the extent of surgery. Rhinology. 2020 Dec 1;58(6):538-543. on rhinosinusitis and nasal polyps 2007. Rhinol Suppl.
doi: 10.4193/Rhin20.165. 2007;20:1-136.
17.Zhang L, Zhang Y, Gao Y, Wang K, Lou H, Meng Y. et 30.Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà
al. Long-term outcomes of different endoscopic sinus I. et al. Efficacy and safety of treatment with biologicals
surgery in recurrent chronic rhinosinusitis with nasal for severe chronic rhinosinusitis with nasal polyps: a
polyps and asthma. Rhinology. 2020 Apr 1;58(2):126-135. systematic review for the EAACI guidelines. Allergy. 2021
doi: 10.4193/Rhin19.184. Aug;76(8):2337-2353. doi: 10.1111/all.14809
18.Delarestaghi MM, Rajaeih S, Firouzabadi FD, Jamali 31.de Vilhena D, Duarte D, Lopes G. Sino-nasal outcome
M, Roomiani M, Firouzabadi MD. et al. Evaluation of the test-22: translation, cultural adaptation and validation in
effect of endoscopic partial middle turbinectomy surgery Portugal. Clin Otolaryngol. 2016 Feb;41(1):21-4. doi: 10.1111/
on the quality of life of patients with chronic rhinosinusitis coa.12465.
and nasal polyps. Rhinology. 2020 Jun 1;58(3):208-212. doi: 32.Doulaptsi M, Prokopakis E, Seys S, Pugin B, Steelant B,
10.4193/Rhin19.258. Hellings P. Visual analogue scale for sino-nasal symptoms
19.Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61(2):253- severity correlates with sino-nasal outcome test 22: paving
60; discussion 261. doi: 10.2165/00003495-200161020- the way for a simple outcome tool of CRS burden. Clin
00008. Transl Allergy. 2018 Sep 3;8:32. doi: 10.1186/s13601-018-0219-6.
20.Pavord ID, Menzies-Gow A, Buhl R, Chanez P, 33.Djupesland PG, Reitsma S, Hopkins C, Sedaghat AR,
Dransfield M, Lugogo N. et al. Clinical development of Peters A, Fokkens WJ. Endoscopic grading systems
mepolizumab for the treatment of severe eosinophilic for nasal polyps: are we comparing apples to oranges?
asthma: on the path to personalized medicine. J Allergy Rhinology. 2022 Apr 11. doi: 10.4193/Rhin21.401
Clin Immunol Pract. 2021 Mar;9(3):1121-1132.e7. doi: 10.1016/j.
jaip.2020.08.039
21.Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA.
Dupilumab: A review of its use in the treatment of atopic
dermatitis. J Am Acad Dermatol. 2018 Mar;78(3 Suppl
1):S28-S36. doi: 10.1016/j.jaad.2017.12.022.
22.Bachert C, Han JK, Wagenmann M, Hosemann W,
Lee SE, Backer V. et al. EUFOREA expert board meeting
on uncontrolled severe chronic rhinosinusitis with
nasal polyps (CRSwNP) and biologics: definitions and

170 Portuguese Journal of Otorhinolaryngology - Head and Neck Surgery